Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study

Int J Cardiol. 2013 Oct 12;168(5):5004-5. doi: 10.1016/j.ijcard.2013.07.121. Epub 2013 Jul 31.

Authors

Pierre Deharo¹, Coline Pons, Mathieu Pankert, Guillaume Bonnet, Jacques Quilici, Charlotte Grosdidier, Shirley Beguin, Pierre Morange, Marie-Christine Alessi, Jean-Louis Bonnet, Thomas Cuisset

Affiliation

¹ Département de Cardiologie, CHU Timone, Marseille F-13385, France; INSERM, UMR1062, «Nutrition, Obesity and Risk of Thrombosis», F-13385 Marseille, France; Aix-Marseille Université, Faculté de Médecine, F-13385 Marseille, France.

PMID: 23915522
DOI: 10.1016/j.ijcard.2013.07.121

No abstract available

Keywords: Acute coronary syndrome; Bleeding; Switch; Very low on treatment platelet reactivity (VLTPR).

Publication types

Letter

MeSH terms

Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / surgery
Clopidogrel
Drug Substitution*
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
Piperazines / adverse effects
Piperazines / therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use*
Prasugrel Hydrochloride
Prospective Studies
Purinergic P2Y Receptor Antagonists / therapeutic use*
Thiophenes / adverse effects
Thiophenes / therapeutic use*
Ticlopidine / adverse effects
Ticlopidine / analogs & derivatives*
Ticlopidine / therapeutic use
Treatment Outcome

Substances

Piperazines
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Thiophenes
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine